245 results on '"Tada, Yuichiro"'
Search Results
202. Identification of the Intraparotid Facial Nerve on Magnetic Resonance Imaging.
- Author
-
Tada, Yuichiro, Inamura, Hiroo, Takahashi, Nobuaki, Sugai, Yukio, and Aoyagi, Masaru
- Subjects
- *
FACIAL nerve , *MAGNETIC resonance imaging - Abstract
As a result of recent advances in magnetic resonance imaging (MRI) technology, direct imaging of the intraparotid facial nerve has become possible. The usefulness of MRI is well known in the diagnosis of parotid tumors. Using a 0.5 T midfield MR unit, this study aimed to visualize the intraparotid facial nerve in 5 normal volunteers and 14 patients with parotid tumors (on 24 normal sides and 14 affected sides). Under appropriate conditions for MRI, the facial nerve was detectable on 9 out of 10 affected sides and 17 out of 20 normal sides. The running course of the facial nerve was consistent with MRI findings in five patients who underwent surgery. The imaging conditions suitable for visualizing the intraparotid facial nerve are reported and the usefulness of MRI in the diagnosis of parotid tumors is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
203. Magnetic Resonance Imaging Findings in a Patient With Bilateral FacialParalysis Due to Malignant Lymphoma.
- Author
-
INAMURA, HIROO, TADA, YUICHIRO, TAKAHASHI, NOBUAKI, and AOYAGI, MASARU
- Subjects
- *
LYMPHOMAS , *MAGNETIC resonance imaging - Abstract
To determine whether the endoscopic stapling technique for the treatment of Zenker's diverticulum provides a relief of symptoms and an acceptably low number of complications. Previous studies have indicated that endosurgical stapling of the common wall between the oesophagus and the diverticulum is a safe and effective method that has a low complication rate and only necessitates a few days of hospitalization. To the present only a few investigations including a limited number of patients have reported the clinical outcome with regard to relief of symptoms and degree of satisfaction in a group of patients treated with this new approach. Twenty-three consecutive patients with Zenker's diverticulum treated with endoscopic staple-assisted oesophagodiverticulotomy were investigated. The median age was 70 years and the median observation time was 12 months. All patients but one (96%), reported significant relief of symptoms and 76% had no symptoms at all at the time of follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2000
204. Magnetic Resonance Imaging Findings in a Patient With Bilateral Facial Paralysis Due to Malignant Lymphoma.
- Author
-
Inamura, Hiroo, Tada, Yuichiro, Takahashi, Nobuaki, and Aoyagi, Masaru
- Subjects
- *
MEDICAL research , *LYMPHOMAS , *CENTRAL nervous system , *MAGNETIC resonance imaging , *INTERNAL auditory meatus , *TRANSCRANIAL magnetic stimulation - Abstract
In malignant lymphomas, especially non-Hodgkin's lymphomas, invasion to the central nervous system (CNS) often occurs. A patient is reported here with bilateral facial paralysis due to invasion of a malignant lymphoma to the CNS. Contrast magnetic resonance imaging (MRI) revealed swelling of the entire length internal auditory meatus and enhancement in the entire length of the facial nerve. Transcranial magnetic stimulation and MRI revealed that later facial nerve injury was present before the onset of paralysis due to a malignant lymphoma. Therefore treatment should be performed with consideration given to the possible invasion of the tumor to the CNS. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
205. Conductance of the hydroxide ion in tert-butyl alcohol-water and 1,4-dioxane-water mixtures.
- Author
-
Tada, Yuichiro, Ibuki, Kazuyasu, Tsuchihashi, Noriaki, and Ueno, Masakatsu
- Abstract
Limiting molar conductances λ
o of potassium hydroxide in 2 to 25 mol% tert-butyl alcohol (TBA)-water mixtures were determined at 25°C as a function of pressure up to 196 MPa. λo ’s of KOH in (2.5 to 15 mol%) 1,4-dioxane-water mixtures at 25°C and 1 atm were also determined. The excess conductance λ of the OH- ion estimated as [λ(OH- ) = λo (KOH) - λo (KCl)] decreased with an increase in the TBA or dioxane content, as did the excess proton conductance λ(H+ ) [λ(H+ ) = λO (HC1) - λo (KCl)]. Although λ(OH- ) is smaller than λ(H+ ) at all solvent compositions studied, the rate of decrease in λ with organic content is larger for the OH- ion than for the H3 O+ ion in both solvent mixtures except in the water-rich region of TBA-water mixtures. λ(OH- ) increases with pressure more strongly in TBA-water mixtures than in pure water, and the rate of increase in λ (OH- ) with pressure has a maximum at 5 mol% of TBA. These results are discussed in terms of the difference in stability of hydrogen bonds between the OH- or the H3 O+ ion and water molecules and the increase in repulsive forces due to the orientation [H-O O-H] of water molecules in the mixtures. [ABSTRACT FROM AUTHOR]- Published
- 1997
- Full Text
- View/download PDF
206. Squeezed bispectrum in the δ N formalism: local observer effect in field space.
- Author
-
Tada, Yuichiro and Vennin, Vincent
- Published
- 2017
- Full Text
- View/download PDF
207. Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis.
- Author
-
Shimoda, Hikari, Teshima, Masanori, Murase, Takayuki, Nagao, Toshitaka, Kusafuka, Kimihide, Nakaguro, Masato, Urano, Makoto, Taguchi, Ken-ichi, Yamamoto, Hidetaka, Kano, Satoshi, Tada, Yuichiro, Tsukahara, Kiyoaki, Okami, Kenji, Onitsuka, Tetsuro, Fujimoto, Yasushi, Kawakita, Daisuke, Sakurai, Kazuo, Hanai, Nobuhiro, Nagao, Toru, and Kawata, Ryo
- Subjects
- *
ADENOID cystic carcinoma , *LYMPHATIC metastasis , *PROGRESSION-free survival , *SURGICAL margin , *PROGNOSIS - Abstract
• We developed prognostic scores for salivary adenoid cystic carcinoma without node metastasis. • Positive surgical margin was proved to significantly predict overall survival. • High histological grade was also proved to significantly predict overall survival. • Prognostic score was determined as the number of positive prognostic factors. • Long-term follow-up is mandatory in patients with PS1 and especially PS2. Adenoid cystic carcinoma (AdCC) of salivary gland grows relatively slowly, but occasionally develops distant metastasis. Although cervical lymph node metastasis (LNM) has been reported as a strong prognostic factor, most of AdCC do not have LNM. In this study, we investigated the prognostic factors to predict disease free survival (DFS), distant metastasis free survival (DMFS), and overall survival (OS) for 175 patients surgically treated for AdCC without LNM, and developed prognostic score (PS) determined as number of positive prognostic factors. The following emerged as significant prognostic factors: positive surgical margin in DFS, pT3/4 and positive surgical margin in DMFS, and positive surgical margin and high-histological grade in OS. 10-year DFS rates were 56.4% in PS0, and 19.1% in PS1 (p < 0.0001). 10-year DMFS rates were 86.3% in PS0, 56.4% in PS1, and 30.7% in PS2 (p < 0.0001). 10-year OS rates were 100% in PS0, 73.3% in PS1, and 38.8% in PS2 (p < 0.0001). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
208. Can massive primordial black holes be produced in mild waterfall hybrid inflation?
- Author
-
Tada, Yuichiro [Institute for Cosmic Ray Research, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa, Chiba 277-8582 (Japan)]
- Published
- 2016
- Full Text
- View/download PDF
209. Non-perturbative approach for curvature perturbations in stochastic δ N formalism
- Author
-
Tada, Yuichiro [Kavli Institute for the Physics and Mathematics of the Universe (WPI), TODIAS, the University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa, 277-8583 (Japan)]
- Published
- 2014
- Full Text
- View/download PDF
210. Primordial black holes as dark matter in supergravity inflation models.
- Author
-
Masahiro Kawasaki, Kusenko, Alexander, Tada, Yuichiro, and Yanagida, Tsutomu T.
- Subjects
- *
DARK matter , *SUPERGRAVITY , *COSMIC background radiation - Abstract
We propose a novel scenario to produce abundant primordial black holes (PBHs) in new inflation which is a second phase of a double inflation in the supergravity framework. In our model, some preinflation phase before the new inflation is assumed and it would be responsible for the primordial curvature perturbations on the cosmic microwave background scale, while the new inflation produces only the small scale perturbations. Our new inflation model has linear, quadratic, and cubic terms in its potential and PBH production corresponds with its flat inflection point. The linear term can be interpreted to come from a supersymmetry-breaking sector, and with this assumption, the vanishing cosmological constant condition after inflation and the flatness condition for the inflection point can be consistently satisfied. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
211. A novel technique of arterial blood flow modification in intra-arterial chemoradiotherapy of maxillary sinus squamous cell carcinoma.
- Author
-
Kanno, Chihiro, Masubuchi, Tatsuo, Fushimi, Chihiro, Kitani, Yosuke, Niwa, Kazutomo, Takeishi, Etsuro, Kaneko, Tetsuharu, Yamazaki, Morio, Hasegawa, Hiroshi, Kamata, Shin-etsu, Miura, Kouki, and Tada, Yuichiro
- Subjects
- *
CHEMORADIOTHERAPY , *BLOOD flow , *MAXILLARY sinus , *SQUAMOUS cell carcinoma , *MAXILLARY artery , *TEMPORAL arteries - Abstract
Objectives: Intra-arterial chemoradiotherapy via a superficial temporal artery is reportedly a useful organ-preserving treatment for maxillary sinus squamous cell carcinoma. This study aimed to determine whether blood flow modification facilitates sufficient drug delivery to the entire carcinoma via the maxillary artery alone, even for advanced tumors.Materials and Methods: A retrospective study of 10 patients who were diagnosed with locally advanced carcinoma (4 [40%] at stage T3, 5 [50%] at T4a, and 1 [10%] at T4b) from August 2016 to July 2018, with tumor blood flow from both the maxillary and facial arteries, was conducted. Patients underwent intra-arterial chemoradiotherapy, which involved chemotherapy with weekly cisplatin administration (40 mg/m2) and radiotherapy (70 Gy/35 fr), with facial artery ligation. The success rate of blood flow modification, as well as its therapeutic effects and safety, were evaluated, with a median follow-up period of 14.4 months (range: 12.3-35 months).Results: The blood flow surrounding the tumor was changed from both the maxillary and facial arteries to the maxillary artery alone in all patients. A median of 9 chemotherapy courses (range: 8-10) were administered; the median total cisplatin dose was 350 mg/m2 (range: 320-360 mg/m2). Radiotherapy of 70 Gy/35 fr was used to treat all patients. Grade 3 oral mucositis (80%) and irradiation field dermatitis (40%) were observed. In all patients, complete response was achieved, and local recurrence was not observed for at least 1 year.Conclusion: Simplifying the blood flow around the tumor facilitates more standardized intra-arterial chemoradiotherapy via a superficial temporal artery procedure. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
212. Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
- Author
-
Hagiwara K, Matsuki T, Okada T, Fushimi C, Kondo T, Takahashi H, Okamoto I, Tokashiki K, Hanyu K, Kishida T, Ito T, Yamashita G, Tsukahara K, Masubuchi T, Tada Y, Momiyama K, Yaguchi R, Oridate N, Omura GO, and Yamashita T
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Retrospective Studies, Antineoplastic Agents, Immunological therapeutic use, Prognosis, Adult, Neutrophils pathology, Aged, 80 and over, Lymphocytes pathology, Antibodies, Monoclonal, Humanized therapeutic use, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck blood, Squamous Cell Carcinoma of Head and Neck mortality, Squamous Cell Carcinoma of Head and Neck pathology, Biomarkers, Tumor blood, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local blood, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms blood, Head and Neck Neoplasms pathology, Head and Neck Neoplasms mortality
- Abstract
Background/aim: The predictive role of hematological markers in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with pembrolizumab remains unclear., Patients and Methods: We conducted a multicenter retrospective cohort study to investigate the predictive impact of the pre-treatment hematological markers neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CRP-albumin-lymphocyte (CALLY) index, and the modified Glasgow prognostic score (mGPS) on overall survival (OS) and progression-free survival (PFS) in patients with R/M SCCHN treated with pembrolizumab. From December 2019 to February 2022, 119 and 28 patients were treated with pembrolizumab alone and pembrolizumab plus chemotherapy, respectively. The optimal cut-off point of dichotomized hematological markers was calculated using the area under the receiver operating characteristic curve. Hazard ratios (HRs) and 95% confidence intervals (95%CIs) were estimated using Cox proportional hazard models with adjustment for potential confounders., Results: In the pembrolizumab monotherapy group, patients with higher NLR, PLR, and mGPS and a lower CALLY index showed significantly shorter OS after adjustment for potential confounders. In addition, all hematological markers examined in this study tended to be associated with clinical response, such as overall response rate or disease control rate (DCR); in particular, a lower CALLY index and higher mGPS were significantly associated with poor DCR. In the pembrolizumab with chemotherapy group, these hematological markers had a similar association with OS but not with clinical response., Conclusion: Pre-treatment NLR, PLR, CALLY index, and mGPS might be predictive markers of survival in patients with R/M SCCHN treated with pembrolizumab., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
213. Comprehensive genomic profiling of salivary gland carcinoma: Analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan.
- Author
-
Iwaki S, Kawakita D, Nagao T, Tada Y, Honma Y, Ando M, Matoba T, Minohara K, Nakano S, Murase T, Iwasaki S, and Inagaki H
- Subjects
- Humans, Male, Female, Japan epidemiology, Aged, Middle Aged, Adult, Receptor, ErbB-2 genetics, Aged, 80 and over, Genomics methods, Cyclin-Dependent Kinase Inhibitor p16 genetics, Tumor Suppressor Protein p53 genetics, Carcinoma, Adenoid Cystic genetics, Carcinoma, Adenoid Cystic pathology, Databases, Genetic, Carcinoma, Ductal genetics, Carcinoma, Ductal pathology, Carcinoma, Ductal therapy, Proto-Oncogene Proteins B-raf genetics, Young Adult, Adenocarcinoma genetics, Adenocarcinoma pathology, Adenocarcinoma therapy, Salivary Gland Neoplasms genetics, Salivary Gland Neoplasms pathology, Salivary Gland Neoplasms therapy
- Abstract
Comprehensive information on genetic alterations in salivary gland cancer (SGC) is limited. This study aimed to elucidate the genetic and clinical characteristics of patients with SGC using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, a Japanese national genomic database. We analyzed data of 776 patients with SGC registered in the C-CAT database between June 1, 2019, and June 30, 2023. Adenoid cystic carcinoma was the most common histologic type, followed by salivary duct carcinoma (SDC) and adenocarcinoma not otherwise specified. Genetic data of 681 patients receiving FoundationOne® CDx were analyzed. We identified specific features of the combination of TP53 and CDKN2A alterations among the histological types. Specific LYN amplification was mainly detected in carcinoma ex pleomorphic adenoma and myoepithelial carcinoma. For SDC, the frequency of ERBB2 and BRAF alterations were higher in cases with metastatic lesions than in those with primary lesions. Although 28.6% patients were offered recommended treatment options, only 6.8% received the recommended treatments. This study highlights the differences in genetic alterations among the histological types of SGC, with comprehensive genomic profiling tests revealing lower drug accessibility. These findings could contribute to the development of personalized treatment for patients with SGC., (© 2024 UICC.)
- Published
- 2024
- Full Text
- View/download PDF
214. PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab.
- Author
-
Matsuki T, Kawakita D, Takahashi H, Okada T, Sakai A, Ueki Y, Tsuge H, Hanyu K, Momiyama K, Shodo R, Yamauchi M, Asako Y, Hirai H, Nagao T, and Tada Y
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Adult, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Prognosis, Neoplasm Metastasis, Antineoplastic Agents, Immunological therapeutic use, Aged, 80 and over, Treatment Outcome, Progression-Free Survival, Antibodies, Monoclonal, Humanized therapeutic use, Salivary Gland Neoplasms drug therapy, Salivary Gland Neoplasms pathology, Salivary Gland Neoplasms metabolism, Salivary Gland Neoplasms mortality, B7-H1 Antigen metabolism, Biomarkers, Tumor metabolism
- Abstract
Although immune checkpoint inhibitors (ICIs) are effective in some patients with salivary gland carcinoma (SGC), biomarkers which predict the efficacy and prognosis of SGC patients treated with pembrolizumab have not been identified. We conducted a multi-institutional retrospective cohort study to evaluate the efficacy and safety of pembrolizumab monotherapy in patients with recurrent and/or metastatic SGC and to determine optimal cut-off values of the combined positive score (CPS) and tumor proportion score (TPS) as numerical expression levels of programmed death-ligand 1 (PD-L1), which predict the efficacy of pembrolizumab. Furthermore, we investigated the association of patient characteristics and hematological markers with clinical outcomes, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). From 2016 to 2021, 27 patients were included in the analysis. ORR of SGC was 25.9%. Optimal cut-off values of CPS and TPS were 15 and 25%, respectively. ORRs of CPS-high and TPS-high were 55.6 and 75.0%, respectively, and significantly higher than those of CPS-low and TPS-low. Furthermore, patients with a low platelet-lymphocyte ratio (PLR) had a significantly longer PFS. No grade 4 or greater adverse events were observed. This study demonstrated the efficacy and safety of pembrolizumab monotherapy and identified optimal cut-off values of CPS and TPS., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
215. Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.
- Author
-
Honma Y, Monden N, Yamazaki K, Kano S, Satake H, Kadowaki S, Utsumi Y, Nakatogawa T, Takano R, Fujii K, Koroki Y, Aoyama J, Ouchi S, Ogawa T, McCarthy S, Brookman-May SD, Mundle S, Li J, Thaper D, Nagao T, and Tada Y
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Aged, 80 and over, Treatment Outcome, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Salivary Gland Neoplasms drug therapy, Salivary Gland Neoplasms pathology, Salivary Gland Neoplasms metabolism, Salivary Gland Neoplasms mortality, Receptors, Androgen metabolism, Thiohydantoins administration & dosage, Thiohydantoins therapeutic use, Thiohydantoins adverse effects, Goserelin administration & dosage, Goserelin therapeutic use, Goserelin adverse effects
- Abstract
Purpose: To assess the efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)-positive unresectable or recurrent/metastatic salivary gland carcinoma., Patients and Methods: This trial was an open-label, single-arm, multicenter phase II study. Patients with histologically confirmed unresectable or recurrent/metastatic salivary gland carcinoma with AR expression were included. The primary endpoint was the overall response rate (ORR) according to RECIST v1.1 by an independent central radiology review in the first 24 response-evaluable (RE) patients who had been observed at least 24 weeks from study initiation (primary RE patients). The efficacy was to be declared when at least 8 of the 24 primary RE patients responded., Results: A total of 31 patients were enrolled. In the first 24 primary RE patients with a median follow-up of 7.4 months, confirmed ORR by independent central radiology review was 25.0% [6/24 patients; 95% confidence interval, 9.8%-46.7%; P = 0.11 (one-sided)], which did not meet the predefined criteria of efficacy. Clinical benefit rate (ORR + rate of stable disease for at least 24 weeks) and median progression-free survival were 50.0% and 7.4 months, respectively. Both median duration of response and overall survival were not reached. Exploratory analyses showed a better ORR of 54.5% (6/11) in patients with AR positivity ≥70% and no history of prior systemic therapy. Grade 3 or higher treatment-emergent adverse events were reported in 35.5% (11/31), which included skin rash, anemia, leukopenia, and cancer pain., Conclusions: Although this study did not meet the predefined efficacy criteria, apalutamide plus goserelin showed clinically meaningful efficacy in a subset of patients with AR-positive salivary gland carcinoma and safety consistent with prior experience in prostate cancer., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
216. The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma.
- Author
-
Kajiwara M, Takahashi H, Nakaguro M, Kawakita D, Hirai H, Utsumi Y, Urano M, Sato Y, Tsukahara K, Kano S, Okami K, Ozawa H, Yamazaki K, Okada T, Shimizu A, Hanyu K, Sakai A, Yamauchi M, Sekimizu M, Hanazawa T, Saito Y, Ueki Y, Honma Y, Arai T, Iwaki S, Yamamura K, Imanishi Y, Sato Y, Tada Y, and Nagao T
- Abstract
Many researchers have focused on the role of the autonomic nervous system in the tumor microenvironment. Autonomic nerves include the sympathetic and parasympathetic nerves, which are known to induce cancer growth and metastasis. However, in salivary duct carcinoma (SDC), a rare and highly malignant tumor, the issue should be investigated from both biological and therapeutic perspectives. We explored the clinicopathological and prognostic implications of the autonomic nerves in 129 SDCs. Immunohistochemistry was performed to determine the nature of each nerve using antibodies against S100, tyrosine hydroxylase (TH) as a sympathetic marker, and vesicular acetylcholine transporter (VAChT) as a parasympathetic marker. The area of each marker-positive nerve was digitized and evaluated quantitatively. Double immunofluorescence for TH and VAChT was performed in selected cases. The expression of the secreted neurotrophins was also examined. S100-positive nerves were present in the cancer tissue in 94 of 129 cases (72.9%). Among them, TH-positive sympathetic nerves and/or VAChT-positive parasympathetic nerves were identified in 92 cases (97.9%), and 59 cases (62.8%) had TH/VAChT-co-expressing nerves. Double immunofluorescence revealed a mosaic pattern of sympathetic and parasympathetic fibers in co-expressing nerve bundles. The presence of autonomic nerves, regardless of their area, was significantly associated with aggressive histological features, advanced T/N classification, and a poor prognosis, with shorter disease-free and overall survival. There was an association between some tumor immune microenvironment-related markers and the autonomic nerve status, but not the latter and the secreted neurotrophin expression. This study suggests that autonomic nerves might play a role in the progression of SDC., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
217. Frequency of and sex differences in cancer treatment-related cardiac dysfunction in trastuzumab-treated patients with salivary gland cancer: a retrospective cohort study.
- Author
-
Tamura Y, Tamura Y, and Tada Y
- Abstract
Background: Trastuzumab treatment for salivary gland, gastric, and breast cancer commonly causes cancer treatment-related cardiac dysfunction (CTRCD). CTRCD incidence by sex has not been well studied., Methods: This retrospective cohort study investigated frequency of and sex differences in CTRCD in patients with salivary gland cancer treated with trastuzumab at our hospital from April 2017 to March 2022. All patients underwent echocardiography at baseline and after the first, third, and sixth trastuzumab courses. We measured changes in global and regional longitudinal strain (LS) after trastuzumab administration. CTRCD was defined by left ventricular ejection fraction (LVEF) or global LS (GLS). The results were compared by sex., Results: We recorded clinical data of 49 patients (median age [IQR], 65 [55-71] years; males [75.5%]). The median follow-up period after the sixth trastuzumab course was 120 (111-128) days. One female patient and no male patient had CTRCD defined by LVEF, and two female patients (16.7%) and seven male patients (18.9%) had CTRCD, defined by GLS. The Kaplan-Meier curves showed no significant difference in CTRCD frequency, defined by GLS (log-rank, p = 0.88), between female and male patients. In the univariate analysis, sex was not associated with CTRCD, defined by GLS. A significant difference in apical LS was observed between baseline and the third follow-up results of male patients., Conclusions: In this study, CTRCD incidence was not significantly different between male and female patients with salivary gland cancer treated with trastuzumab. Although most previous studies have looked at female patients with breast cancer, a male patient may be found to be at similar risk of myocardial damage., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
218. High-grade salivary carcinomas: A current insight on diagnostic pathology and the key to clinical decision making.
- Author
-
Utsumi Y, Nakaguro M, Tada Y, and Nagao T
- Subjects
- Humans, Neoplasm Grading, Carcinoma pathology, Carcinoma diagnosis, Carcinoma therapy, Diagnosis, Differential, Salivary Gland Neoplasms pathology, Salivary Gland Neoplasms diagnosis, Salivary Gland Neoplasms therapy, Clinical Decision-Making
- Abstract
High-grade carcinomas of the salivary glands are a group of several tumor entities with highly malignant histologic appearances, and have an aggressive biological behavior accompanied by poor a prognosis. In general, they require more intensive treatment than low- or intermediate-grade carcinomas. High-grade salivary carcinomas are rare and the microscopic features often overlap between different tumor types, making an appropriate diagnosis challenging in daily practice settings. However, with recent rapid advances in molecular pathology and molecular-targeted therapy in this field, there is a growing need to properly classify tumors, rather than just diagnosing the cases as "high-grade carcinomas". This leads to specific treatment strategies. In this article, we review representative high-grade salivary gland carcinomas, including salivary duct carcinoma and its histologic subtypes, high-grade mucoepidermoid carcinoma, solid-type adenoid cystic carcinoma, and high-grade transformation of low- or intermediate-grade carcinomas, and discuss their differential diagnoses and clinical implications. Other rare entities, such as neuroendocrine carcinoma, NUT carcinoma, and metastatic carcinoma, should also be considered before diagnosing high-grade carcinoma, NOS. Of these tumors, salivary duct carcinoma has received the most attention because of its strong association with androgen deprivation and anti-HER2 therapies. Other tumor-type-specific treatments include anti-TRK therapy for high-grade transformation of secretory carcinoma, but further therapeutic options are expected to be developed in the future. It should be emphasized that detailed histological evaluation with adequate sampling, in addition to the effective use of molecular ancillary tests, is of the utmost importance for a suitable diagnosis., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
219. An autopsy case of pulmonary tumor thrombotic microangiopathy that developed during chemotherapy for salivary duct carcinoma of the parotid gland.
- Author
-
Itoyama M, Ohara A, Yokoyama K, Yamamoto S, Kato K, Tada Y, Sugitani A, Sugino H, Yatabe Y, Kusumoto M, Nakamura K, and Honma Y
- Subjects
- Humans, Male, Adult, Fatal Outcome, Docetaxel therapeutic use, Carboplatin therapeutic use, Carboplatin administration & dosage, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Salivary Ducts pathology, Salivary Ducts diagnostic imaging, Tomography, X-Ray Computed, Thrombocytopenia chemically induced, Androgen Antagonists therapeutic use, Androgen Antagonists adverse effects, Autopsy, Carcinoma, Ductal drug therapy, Carcinoma, Ductal pathology, Thrombotic Microangiopathies chemically induced, Thrombotic Microangiopathies pathology, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Parotid Neoplasms pathology, Parotid Neoplasms drug therapy, Parotid Neoplasms diagnostic imaging, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rapidly progressive cancer-related disease with a dismal clinical course. The patient in this report was a 43-year-old man with metastatic salivary duct carcinoma arising from the parotid gland. Combined androgen blockade therapy was administered started as first-line treatment, but failed after 5 months, followed by docetaxel plus carboplatin therapy as second-line treatment, which failed after 3 months. Genomic profiling revealed a BRAF V600E mutation, and combined BRAF and MEK inhibitor therapy was started as third-line treatment. The cancer remained stable during the first 10 months of third-line treatment, but treatment was subsequently discontinued due to the onset of symptoms of fatigue, myalgia and arthritis. Twenty days after the onset of these symptoms and interruption of third-line treatment, the patient was urgently admitted to hospital with respiratory distress and severe thrombocytopenia. CT images at the time of admission led our radiologist to the possibility of PTTM, but the patient died the day after admission and autopsy findings indicated that PTTM was the cause of death. This report describes a very informative case of PTTM with sequential imaging and detailed autopsy findings were available and provides a literature review., Competing Interests: Declaration of competing interest Three of the authors (Yoshitaka Honma, Ken Kato, Masahiko Kusumoto) declare the following financial interests/personal relationships which may be considered as potential competing interests: 1) Yoshitaka Honma has received compensation as a member of the advisory role of Janssen, Eisai, and Rakuten Medical Japan; received honoraria from Novartis, Chugai pharma, MSD, Ono pharmaceutical, Bristol Myers Squibb, Merck Biopharma, Eisai, Eli Lilly, Nutri, Teijin pharma, Bayer, and Taiho pharmaceutical; and received research funding from Taiho pharmaceutical, Chugai pharma, MSD, GlaxoSmithKline, Janssen, Adlai Nortye Biopharma, Maruho, Merck Biopharma, Genmab, Astellas pharma, Rakuten Medical Japan, and AstraZeneca. 2) Ken Kato reports funding to the institution from Merck Sharp & Dohme Corp (MSD), Ono Pharmaceuticals, Bristol Myers Squibb (BMS), Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai. 3) Masahiko Kusumoto received honoraria for lecture fees from Daiichi-Sankyo Co.,Ltd. Masahiko Kusumoto received a research grant from Canon medical systems corporation., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
220. A Case of Photoimmunotherapy for Nasopharyngeal Carcinoma Requiring Emergency Tracheostomy.
- Author
-
Kushihashi Y, Masubuchi T, Okamoto I, Fushimi C, Yamazaki M, Asano H, Aoki R, Fujii S, Asako Y, and Tada Y
- Abstract
Introduction: Photoimmunotherapy (PIT) is a treatment wherein intravenous cetuximab sarotalocan sodium is administered followed by laser light irradiation. This treatment exhibits a specific antitumor effect if in tumors expressing the epidermal growth factor receptor, regardless of the carcinoma [Mitsunaga et al.: Nat Med. 2011;17(12):1685-91, Sato et al.: ACS Cent Sci. 2018;4(11):1559-69, Nakajima et al.: Cancer Sci. 2018;109(9):2889-96]. The current indications are unresectable, locally advanced, or locally recurrent head and neck cancer. If standard treatments, such as radiotherapy and chemotherapy, are available, they are given priority. However, a significant concern in PIT is the occurrence of airway emergencies related to pharyngeal edema. Prophylactic tracheostomy is often performed in cases of PIT involving the root of the tongue, hypopharynx, or larynx., Case Presentation: In this study, we administered transoral PIT to a patient diagnosed with radiation-induced nasopharyngeal carcinoma (squamous cell carcinoma (SCC) cT1N0M0 stage I). Although previous case reports and our own experiences did not report airway emergencies following PIT for nasopharyngeal carcinoma, a unique case occurred in our study [Omura et al.: Auris Nasus Larynx. 2023;50(4):641-5, Kushihashi et al.: Int J Otolaryngol Head Neck Surg. 2022;11(5, Sep):258-65]. The patient experienced poor oxygenation and a decreased level of consciousness early in the morning following the laser irradiation. Nasal endoscopy revealed airway narrowing due to upper airway edema, and intubation was challenging. Consequently, we performed emergency bedside tracheostomy and the patient's condition improved., Conclusion: Therefore, it is crucial to note that airway emergencies can be life-threatening and should be diligently monitored as a potential complication of PIT., Competing Interests: The authors have no conflicts of interest to declare., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
221. Brain metastases in patients with salivary duct carcinoma: A retrospective study.
- Author
-
Fushimi C, Takahashi H, Kawakita D, Kano S, Tsukahara K, Ozawa H, Okami K, Sakai A, Yamazaki K, Okada T, Hanazawa T, Sato Y, Imanishi Y, Shimizu A, Matsuki T, Nagao T, and Tada Y
- Subjects
- Humans, Retrospective Studies, Salivary Ducts pathology, Prognosis, Salivary Gland Neoplasms pathology, Carcinoma, Ductal pathology, Brain Neoplasms pathology
- Abstract
Background: Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with a 5-year survival rate of 40%. Although drug therapy has improved patients' prognosis, the impact of brain metastasis (BM) remains poorly understood. We aimed to retrospectively examine the incidence of BM in patients with SDC (n = 464) and develop a tool to estimate their prognoses., Methods: We retrospectively examined 464 patients with SDC enrolled in a multicenter study. We investigated the incidence of BM, overall survival (OS) rates, and factors affecting prognosis in patients with BM. We also developed an SDC-graded prognostic assessment (GPA) score for disease prognostication., Results: Sixty-five (14%) patients had BM. The median OS (mOS) was 13.1 months. On univariate and multivariate analyses, factors such as Eastern Cooperative Oncology Group Performance Status >1, human epidermal growth factor receptor 2-negative status, and locoregional uncontrolled disease were associated with poor OS. SDC-GPA scores according to the prognostic factors were 0, 1, 2, and 3 points, and mOS estimates were 50.5, 16.1, 3.9, and 1.2 months, respectively (p < 0.001)., Conclusion: The SDC-GPA score emerged as a useful prognostication tool for patients with BM., (© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
222. The Landscape of MYB/MYBL1- and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma.
- Author
-
Ueda K, Murase T, Kawakita D, Nagao T, Kusafuka K, Nakaguro M, Urano M, Yamamoto H, Taguchi KI, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu KI, and Inagaki H
- Abstract
Approximately 60% of adenoid cystic carcinoma (AdCC) cases are positive for MYB::NFIB or MYBL1::NFIB, whereas MYB/MYBL1 oncoprotein, a key driver of AdCC, is overexpressed in most cases. Juxtaposition of superenhancer regions in NFIB and other genes into the MYB/MYBL1 locus is an attractive oncogenic hypothesis for AdCC cases, either negative or positive for MYB/MYBL1::NFIB. However, evidence supporting this hypothesis is insufficient. We examined 160 salivary AdCC cases for rearrangements in MYB/MYBL1 loci and peri-MYB/MYBL1 areas (centromeric and telomeric areas of 10 Mb each) using formalin-fixed, paraffin-embedded tumor sections. For the detection of the rearrangements, we employed conventional fluorescence in situ hybridization split and fusion assays and a 5 Mb fluorescence in situ hybridization split assay. The latter is a novel assay that enabled us to detect any possible splits within a 5 Mb distance of a chromosome. We found MYB/MYBL1- and peri-MYB/MYBL1-associated rearrangements in 149/160 patients (93%). AdCC cases positive for rearrangements in MYB, MYBL1, the peri-MYB area, and the peri-MYBL1 area numbered 105 (66%), 20 (13%), 19 (12%), and 5 (3%), respectively. In 24 peri-MYB/MYBL1 rearrangement-positive cases, 14 (58%) were found to have a juxtaposition of the NFIB or RAD51B locus into the MYB/MYBL1 loci. On comparing with a tumor group positive for MYB::NFIB, a hallmark of AdCC, other genetically classified tumor groups had similar features of overexpression of the MYB transcript and MYB oncoprotein as detected by semiquantitative RT-qPCR and immunohistochemistry, respectively. In addition, clinicopathological and prognostic features were similar among these groups. Our study suggests that peri-MYB/MYBL1 rearrangements may be a frequent event in AdCC and may result in biological and clinicopathological consequences comparable to MYB/MYBL1 rearrangements. The landscape of MYB/MYBL1 and peri-MYB/MYBL1 rearrangements shown here strongly suggests that juxtaposition of superenhancers into MYB/MYBL1 or peri-MYB/MYBL1 loci is an alteration that acts as a key driver for AdCC oncogenesis and may unify MYB/MYBL1 rearrangement-positive and negative cases., (Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
223. Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma.
- Author
-
Hirai H, Nakaguro M, Tada Y, Saigusa N, Kawakita D, Honma Y, Kano S, Tsukahara K, Ozawa H, Okada T, Okami K, Yamazaki K, Sato Y, Urano M, Kajiwara M, Utsumi Y, Shimura T, Fushimi C, Shimizu A, Kondo T, Imanishi Y, Sakai A, Sato Y, Togashi T, Hanazawa T, Matsuki T, Yamazaki K, and Nagao T
- Subjects
- Humans, B7-H1 Antigen metabolism, CTLA-4 Antigen, Prognosis, Salivary Ducts metabolism, Lymphocytes, Tumor-Infiltrating, Microsatellite Instability, Forkhead Transcription Factors metabolism, Tumor Microenvironment, Salivary Gland Neoplasms pathology, Carcinoma pathology
- Abstract
Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently, immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3, have had a considerable prognostic impact on various malignant tumors. The implementation of such immune checkpoint inhibitor (ICI) therapies has also been attempted in cases of salivary gland carcinoma. The tumor immune microenvironment (TIME) is implicated in tumorigenesis and tumor progression and is closely associated with the response to ICI therapies. However, the TIME in SDC has not been fully explored. We examined the immunohistochemical expression of CD8, FOXP3, PD1, PD-L1, CTLA4, LAG3, and mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI) status in 175 cases of SDC. The associations between these TIME-related markers and the clinicopathological factors and prognosis were evaluated. An elevated expression of CD8, FOXP3, PD1, CTLA4, and LAG3 was associated with more aggressive histological features and an advanced N and/or M classification, elevated Ki-67 index, and poor prognosis. Furthermore, cases with a high PD-L1 expression exhibited more aggressive histological features and adverse clinical outcomes than those with a low expression. Alternatively, there was no significant correlation between TILs and clinicopathological factors. No SDC cases with an MSI-high status or MMR deficiency were found. The coexistence of both an immunostimulatory and immunosuppressive TIME in aggressive SDC might play a role in the presence of T-cell exhaustion. The contribution of multiple immune escape pathways, including regulatory T cells and immune checkpoints, may provide a rationale for ICI therapy, including combined PD1/CTLA4 blockade therapy., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
224. Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
- Author
-
Okada T, Fushimi C, Matsuki T, Tokashiki K, Takahashi H, Okamoto I, Sato H, Kondo T, Hanyu K, Kishida T, Ito T, Yamashita G, Masubuchi T, Tada Y, Miura K, Omura GO, Yamashita T, Oridate N, and Tsukahara K
- Subjects
- Humans, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck drug therapy, Epithelial Cells, Head and Neck Neoplasms drug therapy
- Abstract
Background/aim: Pembrolizumab exhibits anticancer efficacy in platinum-sensitive or platinum-unfit patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, no large-scale retrospective real-world data are available. This retrospective study aimed to examine the efficacy and safety of pembrolizumab in multiple facilities., Patients and Methods: Data of 167 patients with R/M SCCHN treated with pembrolizumab between December 2019 and February 2022 were analyzed. The endpoint was overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs). OS and PFS were analyzed comparatively with and without irAEs, and complete response (CR) or partial response (PR), and stable disease (SD) or progressive disease (PD) were compared., Results: One hundred thirty-five patients received pembrolizumab alone, whereas the others received pembrolizumab with chemotherapy. For the pembrolizumab only group, the median OS and PFS were 22.7 and 5.1 months, respectively. There were significant differences in OS and PFS between CR or PR and SD or PD (p<0.01, p<0.01, respectively). For pembrolizumab with chemotherapy, the OS was not reached and median PFS was 7.0 months. There was a significant difference in PFS between CR or PR and SD or PD (p<0.01). There was a significant difference in PFS between patients with and without irAEs (p=0.02)., Conclusion: The real-world therapeutic effect of pembrolizumab for R/M SCCHN was comparable to that observed in the KEYNOTE048 trial. In addition, irAEs and best overall response were considered as prognostic factors., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
225. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
- Author
-
Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, Tada Y, Sase K, and Hatake K
- Subjects
- Humans, Immune Checkpoint Inhibitors adverse effects, Prospective Studies, Early Detection of Cancer adverse effects, Myocarditis chemically induced, Myocarditis diagnosis, Neoplasms drug therapy, Neoplasms complications
- Abstract
Background: Immune checkpoint inhibitors (ICIs) improve clinical outcomes in various cancers, but sometimes induce autoimmune adverse effects, including myocarditis, which is the most serious complication. There are many reports on ICI-induced myocarditis; however, only a few prospective surveillance reports exist. Therefore, we developed a prospective screening protocol and performed monitoring clinically suspected myocarditis in every patient treated with ICIs., Methods: We prospectively enrolled 126 consecutive patients treated with ICIs in this cohort. Outcomes of patients were determined and analyzed between April 2017 and May 2020. We evaluated vital signs, biomarkers, electrocardiograms, chest radiographs, and echocardiographs before and at 7 ± 3, 14 ± 3, 21 ± 3, and 60 ± 7 days after ICI initiation., Results: Eighteen (14.3 %) presented troponin I elevation and 13 of them presented signs of clinically suspected myocarditis (10.3 %). Among the 13 patients, ICI was discontinued in four cases (3.2 %) without fatal events. Myocarditis appeared at an early stage of ICI treatment, regardless of severity (median, 44 days)., Conclusions: We observed the frequency of patients with myocarditis or myocardial damage through a prospective screening program in the real world. Although the frequency was higher than expected, most cases were mild and ICI treatment could be continued under careful observation., Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
226. Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
- Author
-
Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, Kojima S, Hirai H, Saigusa N, Kano S, Tsukahara K, Togashi T, Ozawa H, Kondo T, Okami K, Takahashi H, Kawakita D, Fushimi C, Suzuki T, Shimizu A, Okamoto I, Okada T, Sato Y, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Urano M, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Shimura T, Nagao T, and Mano H
- Abstract
Molecular targets and predictive biomarkers for prognosis in salivary duct carcinoma (SDC) have not been fully identified. We conducted comprehensive molecular profiling to discover novel biomarkers for SDC. A total of 67 SDC samples were examined with DNA sequencing of 464 genes and transcriptome analysis in combination with the clinicopathological characteristics of the individuals. Prognostic biomarkers associated with response to combined androgen blockade (CAB) treatment were explored using mRNA expression data from 27 cases. Oncogenic mutations in receptor tyrosine kinase (RTK) genes or genes in the MAPK pathway were identified in 55 cases (82.1%). Alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway were identified in 38 cases (56.7%). Interestingly, patient prognosis could be predicted using mRNA expression profiles, but not genetic mutation profiles. The risk score generated from the expression data of a four-gene set that includes the ADAMTS1, DSC1, RNF39, and IGLL5 genes was a significant prognostic marker for overall survival in the cohort (HR = 5.99, 95% confidence interval (CI) = 2.73-13.1, p = 7.8 × 10
-6 ). Another risk score constructed from the expression of CD3E and LDB3 was a strong prognostic marker for progression-free survival for CAB treatment (p = 0.03). Mutations in RTK genes, MAPK pathway genes, and PI3K/AKT pathway genes likely represent key mutations in SDC tumorigenesis. The gene expression profiles identified in this study may be useful for stratifying patients who are good candidates for CAB treatment and may benefit from additional systemic therapies., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
227. Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
- Author
-
Okada T, Matsuki T, Fushimi C, Okamoto I, Sato H, Kondo T, Tokashiki K, Ito T, Masubuchi T, Tada Y, Miura K, Hanyu K, Omura GO, Takahashi H, Yamashita T, Oridate N, and Tsukahara K
- Subjects
- Humans, Neoplasm Recurrence, Local pathology, Nivolumab adverse effects, Platinum therapeutic use, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck drug therapy, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell secondary, Head and Neck Neoplasms drug therapy
- Abstract
Background/aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC., Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups., Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively)., Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
228. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
- Author
-
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, and Tada Y
- Abstract
Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown., Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC., Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB., Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT., Competing Interests: Competing interests: The authors declare that there is no conflict of interest., (© The Author(s), 2022.)
- Published
- 2022
- Full Text
- View/download PDF
229. Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients.
- Author
-
Fukumura M, Ishibashi K, Nakaguro M, Nagao T, Saida K, Urano M, Tanigawa M, Hirai H, Yagyuu T, Kikuchi K, Yada N, Sugita Y, Miyabe M, Hasegawa S, Goto M, Yamamoto H, Ohuchi T, Kusafuka K, Ogawa I, Suzuki H, Notohara K, Shimoda M, Tada Y, Kirita T, Takata T, Morinaga S, Maeda H, Warnakulasuriya S, Miyabe S, and Nagao T
- Subjects
- Biomarkers, Tumor genetics, Humans, In Situ Hybridization, Fluorescence, Japan, Salivary Glands pathology, Adenocarcinoma pathology, Salivary Gland Neoplasms genetics, Salivary Gland Neoplasms pathology
- Abstract
Background: Polymorphous adenocarcinoma is a common intraoral minor salivary gland carcinoma in Western countries but is extremely rare in Japan. The current study aimed to characterize the clinicopathological features and status of molecular alterations of polymorphous adenocarcinoma-associated genes, such as PRKD1/2/3, ARID1A, and DDX3X, in a large cohort of Japanese patients with polymorphous adenocarcinoma., Methods: We examined the cases of 36 Japanese patients with salivary gland polymorphous adenocarcinoma and 26 cases involving histopathological mimics. To detect gene splits, fluorescence in situ hybridization was carried out for polymorphous adenocarcinoma-associated genes. Additionally, we applied a SNaPshot multiplex assay to identify PRKD1 hotspot mutations., Results: This study revealed the indolent clinical course of polymorphous adenocarcinoma with a high 10-year overall survival rate (92.9%), accompanied by occasional local recurrences and cervical lymph node metastasis (23.3%). Twenty cases (55.6%) of polymorphous adenocarcinoma (but none of the mimics) exhibited alterations in at least one polymorphous adenocarcinoma-associated gene. Rearrangement of polymorphous adenocarcinoma-associated genes and PRKD1 E710D were identified in 17 (47.2%) and 4 (11.1%) cases, respectively; one case showed coexisting PRKD3 split and PRKD1 E710D. In the multivariate analysis, high clinical stage (p = 0.0005), the presence of prominent nucleoli (p = 0.0003), and ARID1A split positivity (p = 0.004) were independent risk factors for disease-free survival., Conclusion: Japanese patients with polymorphous adenocarcinoma showed clinicopathological features similar to those reported in Western countries. This study disclosed that polymorphous adenocarcinoma-associated genetic alterations were common and specific findings in polymorphous adenocarcinomas. The diagnostic role and possible prognostic significance of polymorphous adenocarcinoma-associated genetic alterations in polymorphous adenocarcinomas were suggested., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
230. Preoperative S-1 Therapy for Head and Neck Carcinoma During the Waiting Period Before Surgery.
- Author
-
Matsuki T, Fushimi C, Miyamoto S, Takahashi H, Masubuchi T, Tada Y, Miura K, Kamata SE, Kano K, Tsutsumi S, Momiyama K, and Yamashita T
- Subjects
- Humans, Lymphatic Metastasis, Neoadjuvant Therapy, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck surgery, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms surgery
- Abstract
Background/aim: In patients with squamous cell carcinoma of the head and neck (SCCHN), delayed surgery can result in poorer postoperative function and prognosis due to the growth of the tumor and extended surgery. Further, delay may even make the tumor unresectable. To prevent tumor growth during the waiting period before surgery, S-1 has been administrated preoperatively at several facilities in Japan. To date, however, the safety and efficacy of preoperative S-1 remain unclear., Patients and Methods: We conducted a retrospective cohort study of 118 patients with SCCHN treated with S-1 before radical surgery at 2 institutions in Japan. We evaluated the safety of S-1 therapy, which was evaluated by the incidence of grade 3 or greater adverse events (AEs). The rate of achievement of non-growth of tumors was also calculated., Results: Regarding safety, 125 AEs of all grades were recorded in 71 patients (60%). Of these, grade 3 AEs were detected in 3 patients (3%), and no grade 4 or 5 AEs occurred. The nongrowth rate of primary lesions and lymph node metastases was 89% and 85%, respectively., Conclusion: Preoperative S-1 therapy might be useful, with acceptable toxicity, on an outpatient basis in patients with SCCHN., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
231. Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
- Author
-
Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, and Tsukahara K
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Head and Neck Neoplasms immunology, Head and Neck Neoplasms mortality, Head and Neck Neoplasms pathology, Humans, Immune Checkpoint Inhibitors adverse effects, Male, Middle Aged, Nivolumab adverse effects, Progression-Free Survival, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck immunology, Squamous Cell Carcinoma of Head and Neck mortality, Squamous Cell Carcinoma of Head and Neck secondary, Time Factors, Tokyo, Young Adult, Head and Neck Neoplasms drug therapy, Immune Checkpoint Inhibitors administration & dosage, Neoplasm Recurrence, Local, Nivolumab administration & dosage, Squamous Cell Carcinoma of Head and Neck drug therapy
- Abstract
Background/aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data., Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety., Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups., Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
232. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
- Author
-
Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, and Nagao T
- Abstract
Objective: Salivary duct carcinoma (SDC) is a highly aggressive and uncommon tumor arising not only de novo but also in pleomorphic adenoma. Androgen receptor (AR)- and HER2-targeted therapy have recently been introduced for SDC as promising treatment options; however, no predictive biomarkers have yet been established. EZH2 and H3K27me3 are closely linked to the development and progression of various cancers, and EZH2 is also expected to be a desirable therapeutic target. We therefore explored the clinicopathological and prognostic implications of EZH2 and H3K27me3 in a large cohort of SDC patients, focusing on their impact on the therapeutic efficacy of AR- or HER2-targeted therapy., Materials and Methods: The EZH2 and H3K27me3 immunohistochemical expression and EZH2 Y646 gain-of-function mutation status were examined in 226 SDCs, and the relationship with the clinicopathological factors as well as clinical outcomes were evaluated within the three groups depending on the treatment: AR-targeted (combined androgen blockade with leuprorelin acetate and bicalutamide; 89 cases), HER2-targeted (trastuzumab and docetaxel; 42 cases), and conventional therapy (112 cases)., Results: EZH2 and H3K27me3 were variably immunoreactive in most SDCs. A positive correlation was found between the expression of EZH2 and H3K27me3. The EZH2 expression in the SDC component was significantly higher than that in the pre-existing pleomorphic adenoma component. EZH2 Y646 was not identified in any cases. EZH2-high cases more frequently had an advanced clinical stage and aggressive histological features than EZH2-low cases. An EZH2-high status in patients treated with AR-targeted therapy was associated with a significantly shorter progression-free and overall survival as well as a lower objective response rate and clinical benefit rate. In addition, a H3K27me3-high status in patients treated with AR-targeted therapy was related to a shorter overall survival. Conversely, there was no association between the EZH2 and H3K27me3 expression and the clinical outcomes in the conventional or HER2-targeted therapy groups., Conclusions: A high expression of EZH2 and H3K27me3 in SDC might be a predictor of a poor efficacy of AR-targeted therapy. Our data provide new insights into the role of EZH2 and H3K27me3 in therapeutic strategies for SDC., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Saigusa, Hirai, Tada, Kawakita, Nakaguro, Tsukahara, Kano, Ozawa, Kondo, Okami, Togashi, Sato, Urano, Kajiwara, Shimura, Fushimi, Shimizu, Okamoto, Okada, Suzuki, Imanishi, Watanabe, Sakai, Ebisumoto, Sato, Honma, Yamazaki, Ueki, Hanazawa, Saito, Takahashi, Ando, Kohsaka, Matsuki and Nagao.)
- Published
- 2022
- Full Text
- View/download PDF
233. Prognostic Factors of Potential Early Recurrence of Hypopharyngeal Carcinoma.
- Author
-
Baba D, Fushimi C, Hanyu K, Masubuchi T, Tada Y, and Mura K
- Subjects
- Aged, Disease Progression, Disease-Free Survival, Female, Humans, Hypopharyngeal Neoplasms mortality, Hypopharyngeal Neoplasms therapy, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Risk Assessment, Risk Factors, Squamous Cell Carcinoma of Head and Neck mortality, Squamous Cell Carcinoma of Head and Neck therapy, Time Factors, Treatment Outcome, Hypopharyngeal Neoplasms pathology, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck secondary
- Abstract
Background/aim: Prognostic factors of hypopharyngeal carcinoma have been reported previously. However, recurrent cases of this disease occurring within 6 months of treatment have been excluded or poorly documented in many studies. We aimed to evaluate the prognostic factors of hypopharyngeal carcinoma recurrence within 6 months., Patients and Methods: A total of 120 patients were eligible for this retrospective study. Recurrent cases of hypopharyngeal carcinoma occurring within 6 months of treatment were evaluated and compared with non-recurrent cases., Results: Recurrence within 6 months was detected in 28/50 cases. In univariate analyses, classification markers (pT≥4a and cN≥2b) were statistically significant prognostic factors for early recurrence (p=0.04 and p=0.04, respectively); however, only pT≥4a was predictive of recurrence in multivariate analyses (p=0.02)., Conclusion: Risk stratification according to the prognostic factor pT≥4a will allow physicians to identify patients who should be followed meticulously within the first 6 months., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
234. Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade.
- Author
-
Lassche G, Tada Y, van Herpen CML, Jonker MA, Nagao T, Saotome T, Hirai H, Saigusa N, Takahashi H, Ojiri H, van Engen-Van Grunsven ACH, Schalken JA, Fushimi C, and Verhaegh GW
- Abstract
Patients suffering from recurrent or metastatic (R/M) salivary duct carcinoma (SDC) are often treated with combined androgen blockade (CAB). However, CAB frequently fails, resulting in a worse prognosis. Therefore, biomarkers that can predict treatment failure are urgently needed. mRNA from 76 R/M androgen receptor (AR)-positive SDC patients treated with leuprorelin acetate combined with bicalutamide was extracted from pre-treatment tumor specimens. AR, Notch, MAPK, TGFβ, estrogen receptor (ER), Hedgehog (HH), and PI3K signaling pathway activity scores (PAS) were determined based on the expression levels of target genes. Additionally, 5-alpha reductase type 1 ( SRD5A1 ) expression was determined. These markers were related to clinical benefit (complete/partial response or stable disease ≥6 months) and progression-free and overall survival (PFS/OS). SRD5A1 expression had the highest general predictive value for clinical benefit and positive predictive value (PPV: 85.7%). AR PAS had the highest negative predictive value (NPV: 93.3%). The fitting of a multivariable model led to the identification of SRD5A1 , TGFβ, and Notch PAS as the most predictive combination. High AR, high Notch, high ER, low HH PAS, and high SRD5A1 expression were also of prognostic importance regarding PFS and SRD5A1 expression levels for OS. AR, Notch PAS, and SRD5A1 expression have the potential to predict the clinical benefit of CAB treatment in SDC patients. SRD5A1 expression can identify patients that will and AR PAS patients that will not experience clinical benefit (85.7% and 93.3% for PPV and NPV, respectively). The predictive potential of SRD5A1 expression forms a rational basis for including SRD5A1-inhibitors in SDC patients' treatment.
- Published
- 2021
- Full Text
- View/download PDF
235. Resection of Parapharyngeal Space Tumors Located in the Prestyloid Compartment: Efficacy of the Cervical Approach.
- Author
-
Matsuki T, Okamoto I, Tada Y, Masubuchi T, Fushimi C, Kamata S, Miyamoto S, Yamashita T, and Miura K
- Subjects
- Biopsy, Fine-Needle, Humans, Parotid Gland, Retrospective Studies, Adenoma, Pleomorphic surgery, Parapharyngeal Space
- Abstract
Background: Parapharyngeal space tumors are rare. Among them, tumors in the prestyloid compartment are particularly suitable for surgery; however, there are no detailed reports of such surgery and their features remain unknown., Methods: We conducted a retrospective cohort study. For 67 surgical cases of benign tumors in this compartment, we examined the patient and tumor characteristics, fine-needle aspiration cytology (FNAC), and intraoperative details such as surgical approach, use of complete excision, and postoperative complications., Results: Pleomorphic adenomas (PAs) comprised 73.1% of the lesions. The diagnostic accuracy of FNAC to differentiate benign and malignant tumors was 97.7%. Of the treated lesions, 94.0% were removed via the cervical approach alone, including all PAs. The remaining 6.0% were resected via the cervical-parotid approach. The median operative time and bleeding volume were 89 min and 50 mL, respectively. Operative time using the cervical approach was significantly shorter (p = 0.021). All cases could be treated via complete surgical excision. Postoperative complications occurred in 32.8% of patients, with transient slight facial palsy being the most common. No fatal complications occurred and 92.5% of patients had no sequelae. There was no significant association between complications and surgical approach., Conclusion: Based on diagnosis by FNAC, with a high accuracy rate, most benign prestyloid tumors, especially PAs, were resected using the cervical approach alone, with a shorter operative time and without severe complications.
- Published
- 2021
- Full Text
- View/download PDF
236. Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations.
- Author
-
Nakaguro M, Mino-Kenudson M, Urano M, Ogawa I, Honda Y, Hirai H, Tanigawa M, Sukeda A, Kajiwara N, Ohira T, Ikeda N, Mikami Y, Tada Y, Ikeda JI, Matsubayashi J, Faquin WC, Sadow PM, and Nagao T
- Subjects
- Adenoma enzymology, Adenoma pathology, Adenoma surgery, Aged, Biomarkers, Tumor analysis, Biopsy, Bronchial Neoplasms enzymology, Bronchial Neoplasms pathology, Bronchial Neoplasms surgery, DNA Mutational Analysis, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Male, Middle Aged, Predictive Value of Tests, Salivary Gland Neoplasms enzymology, Salivary Gland Neoplasms pathology, Treatment Outcome, Adenoma genetics, Biomarkers, Tumor genetics, Bronchial Neoplasms genetics, Mutation, Proto-Oncogene Proteins B-raf genetics, Salivary Gland Neoplasms genetics
- Abstract
Sialadenoma papilliferum (SP) is a rare benign tumor of the salivary glands, and only 3 unequivocal cases of SP arising in the bronchus have been reported. We herein describe the histomorphologic and molecular features of 4 bronchial SP cases and discuss the differential diagnosis of this entity and the relationship with its clinicopathologic mimics, in particular, glandular papilloma and mixed squamous cell and glandular papilloma (GP/MP). We encountered 2 male and 2 female patients with bronchial SP (mean: 66.8 y old). All 4 tumors arose in the central bronchus and were characterized by a combination of surface exophytic endobronchial papillary proliferation and a submucosal multicystic component with complex architecture. The neoplastic epithelium consisted predominantly of nonciliated stratified columnar cells with ciliated, squamous, and mucinous cells present focally. While 2 tumors (50%) harbored a BRAF V600E mutation by molecular and immunohistochemical analysis, similar to GP/MP, no KRAS, HRAS, AKT1, or PIK3CA mutations were detected in any of the cases. Two patients were treated with limited resection, while 2 patients underwent lobectomy based on the diagnosis of adenocarcinoma or possible squamous cell carcinoma in situ in the preoperative biopsy. All survived without recurrence or metastasis for 23 to 122 months after treatment. SP can develop in the central bronchus as the bronchial counterpart of the salivary gland tumor and should be considered in the differential diagnosis of endobronchial tumors. In addition, some histologic resemblance and frequent BRAF V600E mutation raise the possibility of SP and GP/MP being on the same disease spectrum., Competing Interests: Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
237. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
- Author
-
Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, Fushimi C, Masubuchi T, Miura K, Okazaki SI, Matsui H, Okada T, Iwaki S, Matsuki T, Hanyu K, Tsukahara K, Oridate N, and Tada Y
- Subjects
- Adult, Aged, Aged, 80 and over, B7-H1 Antigen metabolism, Carcinoma, Ductal mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Salivary Gland Neoplasms mortality, Survival Analysis, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Carcinoma, Ductal drug therapy, Immune Checkpoint Inhibitors therapeutic use, Nivolumab therapeutic use, Salivary Gland Neoplasms drug therapy
- Abstract
Although immune-checkpoint inhibitors (ICIs) are effective against various cancers, little is known regarding their role in salivary gland carcinoma (SGC) treatment. Therefore, we evaluated the efficacy and safety of nivolumab monotherapy in patients with recurrent and/or metastatic SGC. In this multicentre retrospective study, nivolumab (240 mg) was administered every 2 weeks. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety were examined; the correlation between treatment outcomes and clinicopathological factors was analysed. Twenty-four patients were enrolled; the most common histopathology was salivary duct carcinoma. Eleven tumours were PD-L1-positive; no tumour was microsatellite instability-high. The ORR was 4.2%, and the median PFS and OS were 1.6 and 10.7 months, respectively. One patient continued nivolumab for 28 months without disease progression. One patient showed grade 4 increase in creatine phosphokinase levels and grade 3 myositis. Biomarker analysis revealed significantly increased OS in patients with performance status of 0; modified Glasgow prognostic score of 0; low neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and C-reactive protein; and high lymphocyte-to-monocyte ratio and in patients who received systemic therapy following nivolumab. Although nivolumab's efficacy against SGC was limited, some patients achieved long-term disease control. Further studies are warranted on ICI use for SGC.
- Published
- 2020
- Full Text
- View/download PDF
238. The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan.
- Author
-
Kawakita D, Murase T, Ueda K, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Matoba T, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Nibu KI, Urano M, Taguchi KI, Nakaguro M, Kusafuka K, Yamamoto H, Nagao T, and Inagaki H
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Adenoid Cystic mortality, Carcinoma, Adenoid Cystic radiotherapy, Disease-Free Survival, Female, Humans, Japan, Male, Margins of Excision, Middle Aged, Multivariate Analysis, Neck Dissection, Neoplasm Recurrence, Local, Parotid Neoplasms mortality, Parotid Neoplasms pathology, Parotid Neoplasms radiotherapy, Parotid Neoplasms surgery, Prognosis, Retrospective Studies, Salivary Gland Neoplasms mortality, Salivary Gland Neoplasms radiotherapy, Treatment Outcome, Young Adult, Carcinoma, Adenoid Cystic pathology, Carcinoma, Adenoid Cystic surgery, Salivary Gland Neoplasms pathology, Salivary Gland Neoplasms surgery
- Abstract
Background: Owing to the low incidence of adenoid cystic carcinoma (AdCC), reliable survival estimates and prognostic factors remained unclarified., Methods: In this multi-institutional retrospective analysis, we collected 192 AdCC cases, and investigated the impact of clinicopathological factors on clinical outcomes of the patients. All AdCC cases were of salivary gland origin and were surgically treated with curative intent. Diagnoses of AdCC were validated by a central pathology review by expert pathologists., Results: The 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5 and 50.0%, respectively. Treatment failure occurred in 89 patients (46%) with the distant failures in 65 (34%). Multivariate analysis indicated that pN2 and a pathologically positive surgical margin were independent prognostic factors for both OS and DFS. Histological grade III was an independent prognostic factor for OS. A primary site in the submandibular gland, pT3/4, pN1, and histological grade II were independent prognostic factors for DFS. Postoperative radiation therapy (PORT) improved the locoregional control (LRC) rate. Prophylactic neck dissection was not associated with a better OS or better LRC among patients with cN0. Facial nerve dissection did not improve clinical outcomes in parotid AdCC cases without facial nerve palsy., Conclusions: A higher TN classification, a pathologically positive surgical margin, and a higher histological grade were associated with a lower OS. PORT improved LRC rates but neck dissection failed to improve clinical outcomes in patients with cN0. As the distant metastasis was frequent, effective systemic therapy is imperative to improve the survival of AdCC patients.
- Published
- 2020
- Full Text
- View/download PDF
239. The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma.
- Author
-
Hirai H, Tada Y, Nakaguro M, Kawakita D, Sato Y, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Okamoto I, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Saigusa N, Takahashi H, Ando M, Urano M, Hanazawa T, and Nagao T
- Subjects
- Adult, Aged, Breast Neoplasms metabolism, Carcinoma, Ductal, Breast metabolism, Female, Humans, Male, Middle Aged, Prognosis, Receptors, Androgen metabolism, Salivary Ducts pathology, Salivary Gland Neoplasms pathology, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Fatty Acid Synthases metabolism, Salivary Ducts metabolism, Salivary Gland Neoplasms metabolism
- Abstract
Salivary duct carcinoma (SDC) is an aggressive, uncommon tumor histologically comparable to high-grade mammary ductal carcinoma. SDCs are usually androgen receptor (AR)-positive and often HER2-positive. Recently, therapies targeting these molecules for SDC have attracted attention. Lipid metabolism changes have been described in association with biological behavior in various cancers, although no such relationship has yet been reported for SDC. We therefore analyzed the clinicopathological relevance of the immunohistochemical expression of adipophilin (ADP) and fatty acid synthase (FASN), representative lipid metabolism-related proteins, in 147 SDCs. ADP and FASN were variably immunoreactive in most SDCs (both 99.3%), and the ADP and FASN expression was negatively correlated (P = 0.014). ADP-positive (≥ 5%) SDCs more frequently exhibited a prominent nuclear pleomorphism and high-Ki-67 labeling index than those ADP-negative (P = 0.013 and 0.011, respectively). In contrast, a high FASN score, calculated by the staining proportion and intensity, (≥ 120) was correlated with the high expression of AR and FOXA1 (P < 0.001 and = 0.003, respectively). The ADP and FASN expression differed significantly among the subtypes based on biomarker immunoprofiling, as assessed by the AR, HER2, and Ki-67 status (P = 0.017 and 0.003, respectively). A multivariate analysis showed that ADP-positive expression was associated with a shorter overall and progression-free survival (P = 0.018 and 0.003, respectively). ADP was associated with an aggressive histopathology and unfavorable prognosis, and FASN may biologically interact with the AR signaling pathway in SDC. ADP may, therefore, be a new prognostic indicator and therapeutic target in SDC.
- Published
- 2020
- Full Text
- View/download PDF
240. Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.
- Author
-
Kawakita D, Tada Y, Imanishi Y, Beppu S, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Shimizu A, Sato Y, Fushimi C, Takase S, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Shimura T, Hanazawa T, Murakami S, and Nagao T
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Japan, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Salivary Gland Neoplasms diagnosis, Salivary Gland Neoplasms therapy, Biomarkers blood, Inflammation Mediators blood, Salivary Ducts pathology, Salivary Gland Neoplasms blood, Salivary Gland Neoplasms mortality
- Abstract
The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models.High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value<0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value<0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.
- Published
- 2017
- Full Text
- View/download PDF
241. Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients.
- Author
-
Otsuka K, Imanishi Y, Tada Y, Kawakita D, Kano S, Tsukahara K, Shimizu A, Ozawa H, Okami K, Sakai A, Sato Y, Ueki Y, Sato Y, Hanazawa T, Chazono H, Ogawa K, and Nagao T
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Ductal surgery, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Salivary Gland Neoplasms surgery, Survival Rate, Carcinoma, Ductal pathology, Salivary Gland Neoplasms pathology
- Abstract
Background: Among salivary gland malignancies, the prognosis of salivary duct carcinoma (SDC) is assumed to be the poorest. However, because of its low incidence, reliable survival estimates and prognostic factors based on a large number of patients remain to be elucidated, thereby making it impossible to standardize the optimal treatment for SDC., Methods: We performed this multi-institutional, retrospective analysis by collecting the clinical information of 141 patients with SDC without distant metastasis who underwent curative surgery as the initial treatment to elucidate overall survival (OS) and disease-free survival (DFS) along with their prognostic factors., Results: The 3-year OS and DFS rates were 70.5 and 38.2 %, respectively. Multivariate analysis revealed that age ≥65 years (p < 0.001) and N1 and N2 (p = 0.047 and <0.001, respectively) were independent prognostic factors for OS, whereas the primary site of the minor salivary and sublingual gland (p < 0.001) and N2 (p < 0.001) were those for DFS. The most common treatment failure was distant metastasis (55 patients, 39.0 %). For early parotid SDC, neither total parotidectomy in the patients with early T stage nor nerve resection in the patients without facial nerve palsy showed survival benefits., Conclusions: Advanced N stage independently affects both OS and DFS. Partial parotidectomy with facial nerve preservation could be a less invasive standard surgical procedure for parotid gland SDC in the early T stage without facial nerve palsy. Effective systemic therapy is imperative to improve DFS of SDC.
- Published
- 2016
- Full Text
- View/download PDF
242. Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy.
- Author
-
Ueki Y, Tada Y, Togashi T, Kawakita D, Nagao T, and Sato Y
- Abstract
Salivary duct carcinoma (SDC) has a poor prognosis owing to the high incidence of distant metastasis. Approximately 40 % of SDCs are positive for human epidermal growth factor receptor 2 (HER2), suggesting that anti-HER2 therapy for cases with distant metastasis may be effective. However, the pathological response of SDC metastases to anti-HER2 therapy has not been reported. A 44-year-old man was diagnosed with HER2-positive SDC of the submandibular gland with multiple distant metastases. After six cycles of trastuzumab/docetaxel therapy, the patient achieved clinical partial response for the primary tumor and complete response for the neck and distant metastases. Subsequently, the patient underwent submandibular gland resection and neck dissection. On histopathological examination, very few viable cancer cells were identified in the resected primary tumor. Unfortunately, the patient died of multiple distant metastases 12 months after initial treatment. Trastuzumab/docetaxel therapy can elicit a clinical and pathological response in HER2-positive SDC., Competing Interests: All authors state that they have no potential conflicts of interest to disclose.For this type of study, formal consent is not required.Informed consent was obtained from the patient included in this report. This study was supported in part by JSPS Grants-in-Aid for Scientific Research (C) to Y. Tada (No. 15K10823).
- Published
- 2016
- Full Text
- View/download PDF
243. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
- Author
-
Masubuchi T, Tada Y, Maruya S, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, and Nagao T
- Subjects
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Salivary Ducts metabolism, Salivary Gland Neoplasms metabolism, ErbB Receptors metabolism, Ki-67 Antigen metabolism, Receptor, ErbB-2 metabolism, Receptors, Androgen metabolism, Salivary Ducts pathology, Salivary Gland Neoplasms pathology
- Abstract
Background: Salivary duct carcinoma (SDC) is a highly aggressive disease which often metastasizes to distant sites, and there is no established standard therapy for this systemic disease. Given that SDC is biologically similar to breast and prostate cancer, anti-androgenic receptor (AR) and anti-human epidermal growth factor receptor 2 (HER2) therapies have the potential to exert effects, not only on patients with breast and prostate cancer but also on those with SDC., Methods: The expression levels of HER2, epidermal growth factor receptor (EGFR), Ki-67, and AR were assessed in 32 patients with SDC, and their correlations with overall survival (OS) and disease-free survival (DFS) were analyzed retrospectively. SDC was classified into five subtypes using a method similar to that used for breast cancer., Results: Anti-AR, HER2, and EGFR were positive in 23 (71.9 %), 14 (43.8 %), and 26 (81.3 %) cases, respectively. One or more of these 3 factors were positive in 30 (93.8 %) cases. The Ki-67 labeling index was greater than 15 % in all cases. While molecular status did not correlate with OS, EGFR and AR positivity were significantly associated with DFS in univariate analysis. Multivariate analysis revealed that EGFR was the only independent predictor of DFS., Conclusions: The statuses of some molecules are useful to predict DFS in patients with SDC. Ki-67 overexpression suggests that cytotoxic agents are effective for SDC. Since the majority of SDCs express AR, HER2, and/or EGFR, assessing and targeting these molecules are promising strategies to improve the prognosis of unresectable, metastatic or recurrent SDC, and a classification system according to the molecular expression status may be useful to select appropriate therapy.
- Published
- 2015
- Full Text
- View/download PDF
244. [Investigation of how to prevent mucositis induced by chemoradiotherapy].
- Author
-
Tosaka C, Tajima H, Inoue T, Moya M, Kobayashi M, Miura K, Tada Y, Masubuchi T, Hushimi C, and Kamata S
- Subjects
- Alanine therapeutic use, Antineoplastic Agents therapeutic use, Combined Modality Therapy adverse effects, Female, Humans, Length of Stay, Male, Middle Aged, Mucositis chemically induced, Alanine analogs & derivatives, Antineoplastic Agents adverse effects, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms radiotherapy, Mouthwashes therapeutic use, Mucositis prevention & control, Quinolones therapeutic use
- Abstract
Chemoradiotherapy for head and neck cancer is associated with a high incidence of severe oral mucositis; an adverse, painful event. Oral mucositis also causes nutritional deficiency by making oral feeding difficult. This may lead to prolongation of hospitalization due to complications caused by malnutrition. However, an effective way to prevent oral mucositis completely, remains to be found. In this study, we evaluated the occurrence of oral mucositis, and nutritional conditions such as hypoalbuminemia, reduction of body weight, and length of hospital stay (days) when the mouth was rinsed using rebamipide solution (R solution), or Poraprezinc-alginate sodium solution (P-A solution) (both considered to be effective for oral mucositis). A mouth rinsed with sodium azulene sulfonate (S solution) was used as a control. The mouth was rinsed out six times per day continuously during chemoradiotherapy. In the study, 31 patients were assigned to rinse their mouths using R solution, 11 patients using PA solution, and 15 patients using S solution (reduction rate of body weight in 14 patients). For the evaluation, the criteria for adverse drug reactions CTCAE (v3. 0) were used. Grade 1 and over, oral mucositis occurred in 48% of the R solution group, 36% of the P-A solution group, and 80% of the S solution group, indicating that the P-A solution group significantly prevented the occurrence of oral mucositis as opposed to the S solution group. A reduction in body weight was observed in 81% of the R solution group, 82% of the P-A solution group, and 79% of the S solution group, indicating a similar weight reduction rate among individual solution groups. Hypoalbuminemia equal to grade 2 or higher occurred in 3% of the R solution group, 18% of the P-A solution group, and 29% of the S solution group, indicating that the R group significantly prevented the occurrence of hypoalbuminemia compared to the S solution group. In addition, the length of hospital stays were 44 ± 8. 0 days for the R solution group, 52 ± 18. 8 days for the P-A solution group, and 61 ± 19. 5 days for the S solution group, indicating that the R solution group significantly shortened the length of hospital stay compared to the S solution group. These results suggested that the use of an R or P-A solution may be effective in preventing oral mucositis and impaired nutrition of those undergoing chemoradiotherapy for head and neck cancer.
- Published
- 2011
245. [Investigation on patient satisfaction at community pharmacies: analyzing questionnaire survey by structural equation modeling and multiple regression analysis].
- Author
-
Sakurai H, Kawahara S, Tada Y, Nakajima F, Igari T, Momose H, Kondo H, Komori Y, and Hayase Y
- Subjects
- Humans, Japan, Models, Statistical, Multivariate Analysis, Regression Analysis, Community Pharmacy Services statistics & numerical data, Health Care Surveys methods, Patient Satisfaction statistics & numerical data, Pharmacies statistics & numerical data, Surveys and Questionnaires
- Abstract
Separation of the dispensing function and the prescribing function, Iyaku Bungyo, has been progressing in Japan. We are now witnessing the advent of a new society where patients select pharmacists and their satisfaction is recognized as one of the healthcare outcome indicators. It is necessary to clarify which factors affect patients' satisfaction with the services provided at community pharmacies and how they do so. A survey was conducted among 104 community pharmacies and their patients around the Tokyo metropolitan area in Japan. The questionnaire comprised 11 items (observed variables), each with a five-grade scale. With the transformed data-oriented pharmacy, the percentage of being not unsatisfactory was examined in two multivariate analyses of the relation and structure of patient satisfaction with a community pharmacy. Structural equation modeling (SEM) with factor analysis (FA) was performed using the observed variables and latent factors. Multiple regression analysis was performed with comprehensive satisfaction as an independent variable, examining the factors that affect comprehensive satisfaction with the pharmacy. The result of the FA indicated three latent factors of instruction on the use of drugs, quality of staff, and environment, based on which SEM model was constructed with a relatively high goodness of fit index. The result of multiple regression analyses indicated almost all variables such as satisfaction with reception by the pharmacist affected the comprehensive satisfaction, but privacy did not show a significant effect. These results, notably the relationship between each variables and latent factors, suggested the importance of higher skills of pharmacists, service qualities at pharmacies, and their functions adjusted to the community.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.